modelEthionamide
Extends from Pharmacolibrary.Drugs.ATC.J.J04AD03.
Information
| name: | Ethionamide | |
| ATC code: | J04AD03 | route: | oral |
| compartments: | 1 | |
| dosage: | 250 | mg |
| volume of distribution: | 1.1 | L |
| clearance: | 40 | L/h |
| other parameters in model implementation | ||
Ethionamide is a second-line antitubercular agent used primarily for the treatment of multidrug-resistant tuberculosis (MDR-TB). It works by inhibiting mycolic acid synthesis, essential for the bacterial cell wall. It is used in combination with other antitubercular drugs and is still approved for clinical use, especially in resistant TB cases.
Pharmacokinetics
Pharmacokinetic parameters in healthy adult volunteers after oral administration.
References
Zhu, M, et al., & Peloquin, CA (2002). Population pharmacokinetics of ethionamide in patients with tuberculosis. Tuberculosis (Edinburgh, Scotland) 82(2-3) 91–96. DOI:10.1054/tube.2002.0330 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12356460
Auclair, B, et al., & Peloquin, CA (2001). Pharmacokinetics of ethionamide administered under fasting conditions or with orange juice, food, or antacids. Antimicrobial agents and chemotherapy 45(3) 810–814. DOI:10.1128/AAC.45.3.810-814.2001 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11181366
Nix, DE, et al., & Peloquin, CA (2004). Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. Tuberculosis (Edinburgh, Scotland) 84(6) 365–373. DOI:10.1016/j.tube.2004.04.001 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15525560
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)